Ozempic vs Wegovy: What's the Difference? (2026)

Ozempic® and Wegovy® contain the exact same active ingredient — semaglutide, made by Novo Nordisk — but they are not interchangeable. Ozempic® is FDA-approved for type 2 diabetes and tops out at a lower dose; Wegovy® is FDA-approved for chronic weight management and goes higher. The molecule is identical; the approval, the maximum dose, and (often) the insurance outcome are not.

Quick comparison

Both are cash-pay through Pallas; not billed to insurance.

Same drug, different approval

Semaglutide is the active ingredient in both products — it's a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a natural gut hormone released after eating, which slows stomach emptying, signals fullness to the brain, and helps regulate insulin. Novo Nordisk developed and markets both under separate brand names because each was studied, dosed, and approved for a different purpose:

• Ozempic® was FDA-approved in 2017 to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It also carries an FDA-approved indication to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and known heart disease.
• Wegovy® was FDA-approved in 2021 for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, alongside diet and exercise. It later gained a separate FDA-approved indication to reduce cardiovascular risk in adults with established cardiovascular disease and obesity or overweight, independent of diabetes status.

For a deeper look at how the underlying hormone biology works, read our explainer on how GLP-1 and GIP work.

Dosing: why the ceilings are different

Both start low and titrate upward over several months to reduce nausea and other GI side effects — but they top out at different doses because they were studied at different doses for different endpoints.

Ozempic® titration (type 2 diabetes):

1. Weeks 1–4: 0.25 mg (treatment initiation — not intended for glycemic control at this dose)
2. Weeks 5–8: 0.5 mg
3. If additional glycemic control is needed after at least 4 weeks at 0.5 mg: 1 mg
4. If additional glycemic control is needed after at least 4 weeks at 1 mg: 2 mg (maximum)

Wegovy® titration (chronic weight management):

1. Weeks 1–4: 0.25 mg
2. Weeks 5–8: 0.5 mg
3. Weeks 9–12: 1.0 mg
4. Weeks 13–16: 1.7 mg
5. Week 17+: 2.4 mg (maintenance)

Your prescribing clinician determines your titration pace and whether to advance to the next step based on how you tolerate each dose — never adjust the schedule yourself.

Can Ozempic® be used for weight loss?

Some clinicians do prescribe Ozempic® off-label for weight loss, since it's the same active ingredient as Wegovy®. This happens in practice, but it comes with real trade-offs worth knowing before you ask for it specifically: Ozempic®'s maximum approved dose (2.0 mg) is lower than Wegovy®'s (2.4 mg), and because Ozempic® is approved and labeled for diabetes, many insurance plans now require a documented type 2 diabetes diagnosis to cover it — coverage isn't automatic just because a prescription exists. Misrepresenting a diagnosis to obtain coverage is insurance fraud with real legal exposure, not a workaround.

If weight management is your actual goal, Wegovy® is the product FDA-approved and dosed specifically for that purpose. Which medication — and which dose — is appropriate for you is a clinical decision a licensed provider makes based on your diagnosis, history, and goals, not a request to route around a formulary.

Side effects: nearly identical

Because they share the same active ingredient and mechanism, the side effect profile is essentially the same for both, with intensity often tracking dose:

Most common:

• Nausea (typically most noticeable in the first 1–4 weeks after starting or after a dose increase)
• Constipation
• Diarrhea
• Vomiting
• Abdominal discomfort

Less common:

• Fatigue, especially early on
• Injection-site reactions
• Gallbladder issues (risk rises with more rapid weight loss)

Rare but serious: pancreatitis, severe allergic reactions, and a boxed warning for both products regarding a potential risk of thyroid C-cell tumors observed in animal studies — both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Most GI side effects ease within 4–8 weeks of starting or after each dose increase. For a full breakdown, see our complete guide to GLP-1 side effects.

Cost comparison

Without insurance, list prices differ because the products are priced and marketed separately, even though the underlying drug is the same:

Novo Nordisk runs a self-pay savings program (NovoCare) that can lower cash cost for eligible patients on either product — ask your pharmacy or clinician what you'd qualify for. Medicare is prohibited by law from covering medications prescribed for weight loss, though it can cover Ozempic® for a documented type 2 diabetes diagnosis.

For the full picture, including compounded semaglutide as a separate, lower-cost option, see our complete semaglutide cost breakdown.

Which one is right for you?

This isn't really an either/or choice — it comes down to why you need semaglutide in the first place:

• You have type 2 diabetes and need glycemic control (with or without a secondary weight-loss benefit): Ozempic® is the product studied and approved for that.
• Your primary goal is chronic weight management, with or without diabetes: Wegovy® is the product studied and approved at the higher dose specifically for that.
• You have both type 2 diabetes and a weight-management goal: your clinician will factor in your diagnosis, insurance situation, and treatment history to recommend the more appropriate product for you.

A US-licensed clinician makes this call based on your history, not a fixed rule — and it's the same clinician who determines your starting dose and titration pace either way.

References

1. U.S. Food and Drug Administration. OZEMPIC® (semaglutide) prescribing information. 2026.
2. U.S. Food and Drug Administration. WEGOVY® (semaglutide) prescribing information. 2026.

Bottom line: Ozempic® and Wegovy® are the same active ingredient, semaglutide, made by the same manufacturer — but they're approved for different reasons, dosed to different ceilings, and priced differently. Ozempic® is for type 2 diabetes; Wegovy® is for chronic weight management. A licensed clinician determines which product, and which dose, fits your diagnosis and goals.